Publications

Journal Article
Research Support, Non-U.S. Gov't
Ppublish 55 citations
Electronic publication date
July 15, 2015

View on Pubmed.gov 25212604 | View on doi.org 10.1158/1078-04...

Human anaplastic thyroid carcinoma cells are sensitive to NK cell-mediated lysis via ULBP2/5/6 and chemoattract NK cells.

Search for publications in this journal Clin Cancer Res - 20(22):5733-44

Abstract

PURPOSE

Anaplastic thyroid carcinoma (ATC) is one of the most aggressive forms of cancer with no curative therapies available. To date, strategies to target ATC by immunotherapy have not been evaluated. We investigated whether ATC would be a suitable target for natural killer (NK) cell-based immunotherapy.

EXPERIMENTAL DESIGN

We first established seven new cell lines from ATC tumors, three from papillary thyroid carcinoma tumors and analyzed them together with eight additional ATC cell lines. Cells were analyzed for sensitivity to lysis by NK cells and their ability to chemoattract and regulate the activity of NK cells. In addition, fresh tumor samples and peripheral blood from six patients with ATC were analyzed for NK cell infiltration and phenotype.

RESULTS

We observed that ATC cell lines are sensitive to lysis by ex vivo expanded NK cells and that the lysis was abrogated upon blockade of NKG2D. Sensitivity of thyroid cancer cell lines to NK cell-mediated lysis correlated with surface expression of UL16-binding protein 2 on tumor cells. Moreover, ATC cell lines produced high levels of CXCL10 and stimulated migration of expanded NK cells and ATC tumors were enriched for NK cells expressing the cognate chemokine receptor CXCR3. However, compared with NK cells in peripheral blood, ATC tumor-derived NK cells displayed a suppressed phenotype with a downregulated expression of NKG2D. In vitro, suppression of NK cell-mediated lysis and NKG2D expression by ATC cells was restored upon neutralization of prostaglandin-E2.

CONCLUSIONS

ATC cell lines are sensitive to NK cell-mediated lysis via ULBP2/5/6 and chemoattract CXCR3-positive NK cells. Patients with ATC may benefit from NK cell-based immunotherapy.

References

No references provided.

Cited by 55 citations (total)

Journal Article Research Support, Non-U.S. Gov't

IL-12 immunotherapy of Braf(V600E)-induced papillary thyroid cancer in a mouse model.

Electronic publication date May 11, 2016

Search for publications in this journal Lab Invest

Ranjit S Parhar [...] Yufei Shi et al.

Papillary thyroid carcinoma (PTC) accounts for >80% thyroid malignancies, and BRAF(V600E) mutation is frequently found in >40% PTC. Interleukin-12 (IL-12)...

Journal Article Research Support, Non-U.S. Gov't

Prostaglandin E2 Secreted by Thyroid Cancer Cells Contributes to Immune Escape Through the Suppression of Natural Killer (NK) Cell Cytotoxicity and NK Cell Differentiation.

Electronic publication date October 1, 2019

Search for publications in this journal Front Immunol

Arum Park [...] Suk Ran Yoon et al.

Natural killer (NK) cells play important roles in immune surveillance. However, the tumor microenvironment suppresses NK cell function and allows...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances

Copyright

©2014 American Association for Cancer Research.